COVID-19 is associated with high blood glucose levels: Diabetic neuropathy during the SARS-CoV-2 pandemic

Abstract

Background: The nerves in the legs and feet are most frequently damaged by diabetic neuropathy. The COVID-19 infection is associated with a high risk of neuropathy symptoms. Case Presentation: On July 12, 2022, a 58-year-old black female retiree with significant symptoms of numbness and muscle weakness in the hands and legs was brought into the emergency room. 17 years prior, she received a type 2 diabetes mellitus diagnosis. Metformin 1.5 g twice a day and glibenclamide 10 mg twice a day were part of her therapy regimen. When she was admitted to the emergency room, she described a one-day history of shortness of breath, frequent urination, excessive thirst, hyperglycemia, excessive appetite, fever, headache, and dehydration. A chest X-ray showed bilateral diffuse, patchy airspace opacities that could be caused by multifocal pneumonia or viral pneumonia. She started receiving 1000 mL of fluid resuscitation (0.9% normal saline) as soon as she was moved to the critical care unit, along with a drip-in insulin infusion. Conclusion: Diabetes, infections like COVID-19, poor vitamin levels, and other factors can all contribute to diabetic neuropathies. According to the Centers for Disease Control and Prevention, patients with type 2 diabetes mellitus are much more likely to experience severe morbidity and death from coronavirus disease-19. Symptoms of diabetic neuropathy continued for months after a COVID-19 infection test resulted in a positive result.

Initiating Immunotherapy in the Treatment of Stage IV Cancers in the Month Before Death—A Health Care Disparities Lens

“…The Kerekes et al data were collected prepandemic. In the present historical context, SARS-CoV-2 continues to transmit at high rates, especially in winter months, and people with advanced cancer are among the most vulnerable . Supportive conversations that increase utilization of vaccines, masking, test-to-treat, and other mitigation may reduce the likelihood of severe COVID-19 outcomes, cancer treatment delays, and treatment discontinuities .…”